Stock VYNE VYNE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 10:40:36 2024-12-11 am EST 		5-day change 1st Jan Change
2.590 USD -1.89% Intraday chart for VYNE Therapeutics Inc. -5.13% +11.16%
Nov. 18 BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target MT
Nov. 07 Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Revenue $121,000 MT

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target
Nov. 18
 MT
Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Revenue $121,000
Nov. 07
 MT
VYNE Therapeutics : Reports Third Quarter 2024 Financial Results and Provides Business Update Form 8 K
Nov. 07
 PU
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Nov. 07
 CI
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov. 07
 AQ
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
Sep. 12
 AQ
VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor
Sep. 12
 CI
VYNE Therapeutics to Participate in September Investor Conferences
Sep. 03
 AQ
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Revenue $198,000
Aug. 14
 MT
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Aug. 14
 AQ
VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
Aug. 14
 CI
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
Jul. 16
 AQ
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
Jul. 09
 AQ
VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
Jul. 09
 CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Index
Jun. 30
 CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell Microcap Index
Jun. 30
 CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell Microcap Value Index
Jun. 30
 CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Value Index
Jun. 30
 CI
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
Jun. 26
 AQ
Arvinas, Inc. Appoints Andrew Saik as Chief Financial Officer
Jun. 24
 CI
Arvinas, Inc. Appoints Andrew Saik as Treasurer
Jun. 24
 CI
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
Jun. 13
 AQ
Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202
Jun. 13
 CI
Top Premarket Gainers
Jun. 07
 MT
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
Jun. 05
 AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VYNE Stock
  4. News VYNE Therapeutics Inc.